

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005) ✓

PCT

(10) International Publication Number
WO 2005/058255 A1 ✓

(51) International Patent Classification: A61K 7/00,
A23L 1/00, A61K 31/352

(21) International Application Number:
PCT/EP2004/014416

(22) International Filing Date:
17 December 2004 (17.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03029183.5 18 December 2003 (18.12.2003) EP

(71) Applicant (for all designated States except US): NESTEC
S.A. [CH/CH]; Avenue Nestlé 55, CH-1800 Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RICHELLE,
Myriam [BE/CH]; Eden-Roc 4, Claires-aux-Moines,
CH-1073 Savigny (CH). OFFORD-CAVIN, Elizabeth
[GB/CH]; Chemin du Rategnau, Haut de Perche B,
CH-1041 Poliez-Pittet (CH). BORTLIK, Karlheinz
[DE/CH]; Chemin de la Cure 36, CH-1510 Syens (CH).
BUREAU-FRANZ, Isabelle [FR/CH]; Rue de la Gare 21,
CH-1110 Morges (CH). WILLIAMSON, Gary [GB/CH];
Route de Servion, CH-1083 Mezières (CH). NIELSEN,
Inge, Lise [DK/CH]; Route des Colodales 58, CH-1820
Montreaux (CH). STELLING, Helke [DE/CH]; Avenue
du Grammont 4, CH-1007 Lausanne (CH). MOODY-
CLIFFE, Angus [GB/CH]; Avenue des Roses 4, CH-1009
Pully (CH).

(74) Agent: CHAUTARD, Cécile; Avenue Nestlé 55, CH-1800
Vevey (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITION FOR IMPROVING SKIN, HAIR AND COAT HEALTH CONTAINING FLAVANONES

(57) Abstract: The present invention pertains to a composition for preventing, decreasing and/or treating skin and hair/coat disorders, such as is effected by inflammatory reactions, environmental factors, ageing or cancer. In particular, the present invention relates to the use of flavanones compounds or their derivatives in nutritional, cosmetic or pharmaceutical compositions for improvement of human or pet animal skin and coat conditions.

WO 2005/058255 A1

COMPOSITION FOR IMPROVING SKIN, HAIR AND COAT HEALTH CONTAINING FLAVANONES

The present invention pertains to a composition for preventing, decreasing and/or treating skin and hair/coat disorders or damages, such as is effected by inflammatory reactions, environmental factors, ageing or cancer. In particular, the present invention relates to the use of flavanones compounds or their derivatives in nutritional, cosmetic or pharmaceutical compositions for improvement of human or pet animal skin and coat conditions.

Background of the invention

The most prominent epithelial tissue in living beings is the skin, which represents the largest organ in the organism. The system of skin integument, which comprises the epidermis, dermis and the stratum corneum, correlates with those of internal organs and concurrently interacts with the surroundings. Being the interface between the environment and organism itself, the skin is heavily influenced by external factors and also variable parameters of the organism's inner system. The skin's regulative mechanisms need, therefore, always be active to induce systemic changes necessary to maintain normal pathological events concerning skin integument morphology and activities.

A great deal of processes assuring the adequate consumption of increased affluence of energetic and plastic substances according to the skin's needs become guarantors of morphological and functional stability of skin structures. So, the state of integuments determines the realization of metabolic processes necessary for skin cell viability and activity leading to the presence of healthy skin peculiarities such as barrier function, elasticity, turgor properties, humidity, pigmentation etc..

During the lifetime of a living being different signs, characteristic of ageing, appear on the skin or hair, with the principal clinical signs being the appearance of fine lines and deep wrinkles which increase or are accentuated with age, loss of hair, reduced hair density, glossiness, color, oiliness, fiber diameter, etc....

These signs of ageing are even promoted by exposure of the skin and hair to exogenous influences, such as e.g. UV-radiation, pollutants, free radicals or chemical substances.

- 5 In the art several means have been proposed to prevent destructive effects of environment or ageing on skin epithelial cells. For example, means to prevent skin deterioration or ageing is to provide compounds scavenging free radicals. In this respect EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.
- 10 Although there is a great diversity of active compounds for ameliorating skin and hair or coat health, there still exists a need in the art to provide new active compounds. In particular, an object of the present invention is to provide compositions that may be used over a long period of time by humans or pets, and susceptible to be provided in the form of a nutritional supplement, for example a nutritional composition.

15

Summary of the invention

- In a first aspect, the present invention relates to a nutritional, cosmetic or pharmaceutical composition for human or pets, which contains as active compound, at least one flavanone compound or its derivatives, or a mixture thereof, in an efficient amount to prevent, treat or
20 alleviate skin, hair and/or coat disorders and ameliorate skin, hair and coat health.

- In another aspect, the invention provides the use of at least one flavanone or its derivatives or mixtures thereof, as active compound in the preparation of a nutritional, cosmetic or
25 pharmaceutical composition intended for preventing or treating skin, hair and/or coat disorders, thus ameliorating skin health conditions in humans or pets.

- The composition according to the present invention may be in the form of a complete nutritional formula, a dietary supplement to be orally administered to a human or an animal,
30 or a compound for pharmaceutical use.

Administering to a human or pet animal, a food composition as described above, results in an improved skin health, e.g. on photoprotection, hydration, dryness, firmness, thickness, elasticity, oilness, regular pigmentation, immunity or hair and coat health, e.g. improving hair and coat gloss, hair density, color, oilness, ameliorating hair fibre diameter, sebum production, glossiness and preventing hair and coat loss. Also, the composition according to the present invention is administered to a human or an animal, for ameliorating antioxidant status, barrier function, to prevent or modulate oxidative status, sebum production or composition, or to reduce signs of ageing. It also helps to reduce risks of cancer or inflammation.

Detailed description of the invention

According to the first object, the invention provides a nutritional, cosmetic or pharmaceutical composition for oral administration for human or pets, which contains as active compound, at least one flavanone compound or its derivatives, or a mixture thereof, in an efficient amount to prevent, treat or alleviate skin, hair and/or coat disorders or damages and thus ameliorate skin, hair and coat health.

The flavanone compounds of interest are natural glycosides that can be found principally in fruits from the genus Citrus, such as orange, lemon, bitter orange, grapefruit, for example or in a lesser extend in other vegetables. They are present in majority in the peel of the fruit, but also in large amounts in the pulp and thus also in citrus fruit juice. The compounds according to the present invention may be isosacuranetin, naringin, hesperidin, or eriodictyol, poncirin, neoeriodictin, for example, and their derivatives selected from their aglycone forms, chalcone forms, glycosylated forms or methylated forms. Also, their sulfated or glucuronidated forms which are found as product of metabolism in blood are used.

In a last aspect, derivatives may be obtained by several processes known in the art, such as enzymatic treatments. For example, glucose-7-hesperetin is prepared by rhamnosidase or hesperidinase treatment.

The flavanone compound or derivatives according to the invention may be included in any composition suitable for administering the substance to an individual, in particular a food composition, a cosmetic composition or a pharmaceutical composition.

5

In a preferred embodiment, a food composition for human consumption is prepared. This composition may be a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, soup, a dietary supplement, a meal replacement, and a nutritional bar or a confectionery. The composition may be selected from the group consisting of milk, or
10 fermented milk products, such as e.g. yogurt, curd, cheese, milk based fermented products, ice-creams, milk based powders, infant formulae, cereal products and fermented cereal based products, beverages, mineral water, chocolate or pet food containing at least a flavanone compound or one of its derivatives. The nutritional supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions.
15 Methods for preparing them are common knowledge.

As described above, flavanones compounds are found naturally in Citrus fruits, in particular in oranges, lemons and grapefruit, in their peel or pulp. Accordingly, in a first aspect, the nutritional composition may be in the form of a juice of such fruits or in the form of a
20 concentrate. Thus, the nutritional composition may be in the form of any food product, in particular any beverage, citrus juice or any other extract from peel or pulp of citrus fruits.

In another embodiment, a usual food product may be enriched with the flavanones, preferably in the form of citrus extract. For example, a fermented milk, a yoghurt, a fresh
25 cheese, a renneted milk, a confectionery bar, breakfast cereal flakes or bars, drinks, milk powders, soy-based products, non-milk fermented products or nutritional supplements for clinical nutrition. In particular, a process for preparing an extract enriched if flavanones, in particular hesperidin, from orange and lemon is described in US N02,400,693 and US 2,442,110, respectively.

30

According to a further aspect, flavanones compounds to be included in the specification may be synthetically produced.

5 A nutritional composition according to the present invention may comprise the flavanone compounds, its derivatives or mixtures thereof in an amount adapted to a daily oral administration, and of from about 0.01 mg to 1g, preferably from about 0.1 mg to 800 mg, more preferably from 10 mg to 800 mg of the aglycone equivalent of the flavanone compound.

10 The flavanones according to the invention may be used either alone or in association with other active compounds such as vitamin C, vitamin E (tocopherols and tocotrienols), carotenoids (carotenes, lycopene, lutein, zeaxanthine, beta-cryptoxanthine, etc ..) ubiquinones (e.g.CoQ10), catechins (e.g. epigallocatechin gallate), coffee extracts containing polyphenols and/or diterpenes (e.g. kawheol and cafestol), extracts of chicory, ginkgo biloba extracts,
15 grape or grape seed extracts rich in proanthocyanidins, spice extracts (e.g. rosemary), soy extracts containing isoflavones and related phytoestrogens and other sources of flavonoids with antioxidant activity, fatty acids, e.g. n-3 fatty acids, prebiotic fibers, probiotic microorganisms, taurine, resveratrol, aminoacids, selenium and precursors of glutathione, for example.

20

In another embodiment, a pharmaceutical compositions can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described herein under, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount
25 adequate to accomplish this is defined as "a therapeutically effective dose". Amounts effective for this will depend on the severity of the disease and the weight and general state of the patient.

In prophylactic applications, compositions according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease. Such an amount is defined to be
30 "a prophylactic effective dose". In this use, the precise amounts again depend on the patient's

state of health and weight. Preferably, for humans the pharmaceutical composition according to the present invention comprises an amount of flavanone compounds, its derivatives or mixture thereof as described above, for a daily administration, from about 0.01 mg to 500 mg. When administered daily to pets, the composition may comprise from 1 mg to 500 mg of the aglycone equivalent of flavanone compounds.

The compounds of the invention are preferably administered with a pharmaceutical acceptable carrier, the nature of the carrier differing with the mode of administration, for example parenteral, intravenous, oral and topical (including ophthalmic) routes.

It will be appreciated that the skilled person will, based on his own knowledge select the appropriate components and galenic form to target the active compound to the skin or hair taking into account the route of administration which may be by way of injection, topical application, intranasal administration, administration by implanted or transdermal sustained release systems, and the like.

The objective substance may also be formulated in a cosmetic product, such as lotions, shampoos, creams, sun-screens, after-sun creams, sun-blocker, anti-ageing creams and/or ointments. It will be appreciated that the present cosmetic products will contain a mixture of different ingredients known to the skilled person, ensuring a fast penetration of the objective substance into the skin and preventing degradation thereof during storage.

It will be understood that the concept of the present invention may likewise be applied as an adjuvant therapy assisting in presently used medications. Since the compounds of the present invention may easily be administered together with food material special clinical food may be applied containing a high amount of the objective substances. It will be clear that on reading the present specification together with the appending claims the skilled person will envisage a variety of different alternatives to the specific embodiments mentioned herein.

In principle, the compounds according to the present invention may be used for the treatment

and/ or prevention of damages in the skin which are produced by a stress situation e.g. by means of a chemical, biological or a physical stress, e.g. by exposure to oxidants or carcinogens, exposure to bacteria, viruses, fungi, lipids derived from surrounding cells and/or microbes, or exposure to UV-irradiation.

5

Consequently, the substances and/or compositions according to the present invention may be utilized for treating and or preventing damages of the skin, in particular actinic and ageing damages of the skin such as dryness, actinic keratoses, irregular pigmentation (notably comprising freckling, lentigines, guttate hypomelanosis and persistent hyperpigmentation),
10 wrinkling (notably comprising fine surface lines and deep furrows), stellate pseudoscars, elastosis, inelasticity, telangiectasia, venous lakes, purpura, comedones, sebaceous hyperplasia, acrochordon, cherry angioma, seborrhea keratosis, lentigo, basal cell carcinoma and squamous cell carcinoma, skin burning and/or blistering, epidermal hyperplasia, inflammation, immune suppression, and cancer, e.g. non-melanoma and
15 melanoma skin cancers. They have also particular benefits on hair and coat, such as an improved hair or coat density, fiber diameter, color, oilness, glossiness, sebum production and a helps to prevent hair or coat loss.

The effect of a food supplementation in flavanones compounds or its derivatives according to
20 the present invention, on skin of humans or pets, can be measured by using conventional methods including minimal erythral dose (MED), colorimetry, transepidermal water loss, DNA repair (e.g.p.53), measure of interleukines and proteoglycans production, or collagenase activity, barrier function or cell renewal.

25 The following examples illustrate the invention in more detail without restricting the same thereto. They are preceded by a brief description of the Figures.

Fig. 1: HaCat cells were incubated with 10 μ M hesperetin (hp, red bars) or 10 μ M hesperetin-7-O-glucuronide (hp-7-O-gluc, yellow bars) or equal amounts of DMSO as a control (blue bars) and treated with or without menadione for additional 5h. The supernatant was analyzed
30

for lactate dehydrogenase (LDH) activity and results were expressed relative to cells which were lysed with triton-X100 before analysis (100% death).

Fig. 2: Chart representing the experimental set-up of the hesperidin growth trial.

Fig. 3: Histopathological analysis of rat skin supplemented with hesperidin. 6µm paraffin sections were de-waxed, stained with hematoxylin/eosin and mounted. Representative images in two magnifications are shown for the control group (A and D) and the groups supplemented with hesperidin (0.1%: B and E, 0.5% C and F).

Fig. 4: Real-time PCR analysis of total RNA isolated from rat skin fed either a control diet (ctrl) or a hesperidin-supplemented diet (0.1% Hp, 0.5% Hp) for the expression of CD1d1 and interleukin 6 (IL-6). Samples were analyzed in 3 pools containing 4 rats each and obtained Ct values are shown for CD1d1 in A and IL-6 in B. Dots represent averages of technical triplicates, bars the total average per group. Fold changes in relative expression of the supplementation compared to control diet and relative to a housekeeping gene are shown in C. The control diet was set to 1 fold and is represented by a thick line. Confident intervals were calculated using ANOVA.

Example 1 : mineral water supplemented with flavanone

A mineral water is prepared by adding hesperetin-7-glucose, in an amount of 0.01 mg to 200 mg per liter, estimating that the average consumption is of about 1 liter per day.

Example 2: Cosmetic for oral administration

A composition in the form of a hard capsule has the following formulation:

Compound	mg per capsule
Hesperidine (hesperetin equivalent)	250
Excipient for the core	
Cellulose microcrystalline	70
Encompress TM	60
Stéarate de Magnesium	3
Silice colloïdale anhydre	1
Coating agent	
Gum-lac	5
Talc	61
Sucrose	250
polyvidone	6
titanium dioxide	0.3
coloring agent	5

The composition can administered to the individual in an amount of 2 to 3 capsules daily.

Example 3: Canned Pet food and supplement

5

A mixture is prepared from 73 % of poultry carcass, pig lungs and beef liver (ground), 16 % of wheat flour, 7 % of water, 2 % of dyes, flavours, vitamins, and inorganic salts. This mixture is emulsified at 12°C and extruded in the form of a pudding which is then cooked at a temperature of 90°C. It is cooled to 30°C and cut in chunks. 45 % of the chunks are mixed with 55 % of a sauce prepared from 98 % of water, 1 % of dye and 1% of guar gum. Tinplate cans are filled and sterilized at 125°C for 40 min.

10

As a supplement to be mixed with the pet-food before serving, additional packaging in sachet form with 50 mg of hesperetin equivalent, in the form of Citrus extract is provided. This is supplied as a supplement with removably attached to the can, together with feeding directions.

15

Example 4: Functional food

A food supplement was prepared by mixing or blending fructooligosaccharide with inulin in

- the proportions by weight of about 70% fructooligosaccharide to about 30% inulin and adding 500 mg of hesperetin equivalent. The resulting prebiotic mixture may be added or blended with any suitable carrier, for example a fermented milk, a yogurt, a fresh cheese, a renneted milk, a confectionery bar, breakfast cereal flakes or bars, a drink, milk powder, soy-based product, non-milk fermented product or a nutritional supplement for clinical nutrition.

Example 5

Material and Methods

10 Cytotoxicity Assay

- Human immortalized keratinocytes (HaCaT) were incubated with 10 μ M hesperetin, 10 μ M hesperetin-7-O-glucuronide or equal amounts of DMSO as a negative control for 16h and 1h before challenge. Cells were then treated with 100 μ M menadione, a xenobiotic which
15 generates reactive oxygen species intracellularly. Non-menadione treated cells were used as a positive control. After 5h the supernatant was analysed for lactate dehydrogenase (LDH) activity as a measure for cell death using the CytoTox 96 non-radioactive cytotoxicity assay (Promega, USA).

20 Skin samples

Rat skin biopsies were obtained from the Heperidin growth trial (Fig.2). Dorsal skin was excised, one part was fixed in 4% PFA and paraffin embedded, one part was cryo-preserved and another part was immediately frozen in liquid nitrogen.

25

Histology

Paraffin sections

- Rat skin was dissected and fixed for 4 days in 4% paraformaldehyde in PBS (pH 7.4) at 4°C
30 and embedded in paraffin using a Leica Microsysteme embedding apparatus. The tissues

were washed in PBS and saline (0.9% NaCl) and dehydrated by passing them through saline solutions with increasing ethanol concentrations: 30 min each in 30%, 50%, 70%, 90%, 99%, 100% and an additional hour in 100%. Tissue samples were incubated twice for 30 min in xylene, followed by 2-3 h and 3 h incubations in paraffin wax at 60°C. 6 µm thick paraffin sections were cut using a Leica Microtome. Sections were de-waxed 5 min in xylene and dehydrated by passing them through a series of solutions with decreasing ethanol concentrations: 1 min each in 100%, 96%, 90%, 80%, 70%, and 50% ethanol. Finally, they were transferred into distilled water and stained.

10 *Hematoxylin/eosin staining*

Rehydrated sections were stained for 45 sec in Mayer's hematoxylin solution, rinsed with the following series of solution for 1 min each: distilled water, tap water, distilled water and 70% ethanol. After staining 10 sec in eosin solution (1% (v/v) in 90% ethanol) sections were rinsed in 90% and 100% ethanol. Following two 10 min incubations in xylene, coverslips were mounted with Eukit and air-dried for 2 h at room temperature.

RNA Methods

General directions for working with RNA

20

For experiments with RNA, sterile plastic or baked glass vessels (180°C for at least 8h) have been used. All surfaces were cleaned with RNase ZAP prior use, including pipetmen, and aerosol resistant tips were used only.

Equipment

25

ABI PRISM[®] 7000HT Sequence Detection System, Applied Biosystems, USA
ABI PRISM[®] 7000 RT-PCR software, Applied Biosystems, USA
PCR Cycler, e.g. PTC-100 Programmable Thermal Controller, MJ Research Inc., USA
Agilent 2100 bioanalyzer, Agilent Technologies, USA
30 Fluorescence Plate Reader, e.g. Spectra Fluor Plus F 129005, Tecan, USA

Multifuge 3S, Heraeus with special buckets for MFC centrifugation, Kendro Laboratory Products, Switzerland
Cooling Centrifuge, e.g. Centrifuge 5417R, Eppendorf, Germany

5 *Reagents*

- Totally RNA Kit (Art. No. 1910), Ambion, USA
Lysing Matrix D (Art. No. 6913-100), Q BIogene, France
RNA 6000 Nano Assay (Art. No.5065-4475 and 5065-4476), Agilent Technologies, USA
- 10 Assays-on-demand (20x stock, Applied Biosystems, USA)
RNase ZAP (Art. No. 9780), Ambion, USA
Nuclease-free water (ddH₂O, Art. No. 9939), Ambion, USA
Milli-Q filtered water (0.22μM, ddH₂O)
Ethanol, GR for analysis (Art. No. 02860), Fluka
- 15 Dulbecco's phosphate buffered saline (PBS, Art. No. D8537), Sigma
β-Mercaptoethanol (Art. No. M7522), Sigma, USA
RiboGreen RNA Quantitation Kit (Art. No. R-11490), Molecular Probes, USA
SUPERase-In RNase Inhibitor (20U/μl, Art. No. 2694), Ambion, USA
SuperScript II RNase H⁻ reverse transcriptase (200U/μl, Art. No. 18064-014), Invitrogen, USA
- 20 First-strand buffer (5x): 250mM NaCl, 0.1mM EDTA, 1mM DTT, 0.1% (v/v) NP-40, 50% (v/v) glycerol, included with SuperScript II RNase H⁻ reverse transcriptase
Dithiothreitol (DTT, 1mM), included with SuperScript II RNase H⁻ reverse transcriptase
2'-Deoxyadenosin-5'-triphosphate (dATP, 100mM, Art. No. 272050), Amersham Biosciences, England
- 25 2'-Deoxycytidine-5'-triphosphate (dCTP, 100mM, Art. No. 272060), Amersham Biosciences, England
2'-Deoxyguanosine-5'-triphosphate (dGTP, 100mM, Art. No. 272070), Amersham Biosciences, England
2'-Deoxythymidin-5'-triphosphate (dTTP, 100mM, Art. No. 272080), Amersham Biosciences, England
- 30 England

pd(N)₆ Random hexamer (Art. No. 27-2166-01), Amersham Biosciences, England
 TaqMan Universal PCR Master Mix (Art. No. PN4304437), Applied Biosystems, USA

Gene name	Gene symbol	Reference sequence	Assay ID
interleukin 6	Il6	NM_012589	Rn00561420_m1
CD1d1 antigen	Cd1d1	NM_017079	Rn_00567162_m1
proliferating cell nuclear antigen	Pcna	NM_022381	Rn00574296_g1
glyceraldehyde-3-phosphate dehydrogenase	Gapd	NM_017008	Rn99999916_s1

Tab. 1: Assays-on-demand used (Assay ID), including Gene names, genes

5 symbols and reference sequences.

RNA extraction

Skin samples were homogenized with Lysing Matrix D, total RNAs were extracted using the Totally RNA Kit following the manufacturer's instructions. RNA was eluted with 40µl of nuclease-free water.

10

RNA quantification

The quantification was performed using the Ribogreen[®] RNA quantitation Kit on 96-well plates and a fluorescence microplate reader according to the manual. Measurements were done in duplicate. The samples were diluted either 1:680 or 1:3400 in a final volume of 100 µl 1xTE buffer. Dilutions of the ribosomal RNA in a concentration of 1, 0.5, 0.1, 0.02, 0 µg/ml were used as standards. Integrity of 1µl RNA was controlled using RNA 6000 Nano Assay.

15

Reverse transcription

20 All manipulations were done on ice. 2µl pd(N)₆ random hexamers and 1µl dNTP (10mM)

were added to 2µg RNA in nuclease-free water in a final volume of 12µl. After 5min incubation at 65°C, samples were immediately placed on ice and quickly centrifuged. Then, 4µl of 5X first strand buffer, 2µl of dithiothreitol, 1µl of RNase inhibitor and 1µl of reverse transcriptase SuperScript II RNase H⁻ were added (final volume 20µl). The reverse transcription reaction was performed in a PCR cycler using the following temperature program: activation of the enzyme: 10min at 25°C; reverse transcription reaction: 60min at 42°C; inhibition of the enzyme: 20min at 70°C. The sample was then kept in the freezer at -20°C until further use.

10 *Real-time polymerase chain reaction*

The real-time PCR was performed according to the TaqMan[®] method in 96 well plates (96WP) using assays-on-demand primer and probes. Analysis was done in triplicate using a master mix (3.5x) which contained 43.7µl TaqMan[®] 2x Universal PCR master mix, 4.4µl assays-on-demand primers and probes, 21.9µl nuclease-free water and 17.5µl cDNA (87.5ng = 25ng per replicate). Triplicates of 25µl master mix were loaded on a 96 well ABI PRISM reaction plate, covered with a transparent optical adhesive cover and centrifuged three times at 2000rpm for 1min or until all air-bubbles had been removed. The PCR reaction was then performed in the ABI PRISM[®] 7000 Sequence Detection System using the following temperature program: activation of the enzyme: 2min at 50°C; denaturation: 10min at 95°C and 40 cycles target amplification: 15sec annealing at 95°C and 1min extension at 60°C. The analysis of the amplification plots was done using the ABI PRISM[®] software Baseline adjustments were done individually (Il6: 15-25, Cd1d1: 10-20, Pcn1: 15-25; Gapd: 6-15), whereas thresholds were set manually at 0.2 for all primers. The resulting Ct values were exported into Microsoft Excel for further analysis.

25

Statistical analysis

Data were analysed by ANOVA.

Results and Discussion

- In vitro experiments using immortalized keratinocytes (HaCat) demonstrated that treatment with hesperetin (hp) and hesperetin-7-O-glucuronide (hp-7-O-gluc) is reducing cell death under normal culture conditions. The protective effect of hp and hp-7-O-gluc was even more pronounced in cells challenged with menadione, a xenobiotic which increases intracellular levels of reactive oxygen species (ROS). Moreover, hp-7-O-gluc, the main metabolite of hesperidin in blood, seems to be more potent compared to hp, the aglycone (Fig. 1).
- 10 The protective effect of hesperidin was further investigated in an animal interventional trial using growing femal wistar rats. After weaning, rats were randomized in 3 groups with 12 animals each and supplemented with either a control diet, or a hesperidin supplemented diet using two different doses (0.1% and 0.5%). At the age of 12 weeks rats were sacrificed and skin tissue was used for skin histology and mRNA analysis (Fig. 2). Histopathological
- 15 analysis of the skin revealed a reduced number of inflammatory cells in animals fed the hesperidin diet. Representative images are shown in Fig. 3 (3A+D (control) vs. 3B+E (0.1% hesperidin) vs. 3C+F (hesperidin)). These histological observations could be confirmed at the mRNA level. Rat fed 0.5% hesperidin showed significantly reduced levels of IL-6, an inflammatory cytokine (Fig. 4A+C). In addition CD1d1 mRNA levels were significantly
- 20 decreased in both groups supplemented with hesperidin (Fig. 4B+C).

These data clearly demonstrate cytoprotective and anti-inflammatory properties of orally administrated hesperidin for skin.

Claims

1. A nutritional, cosmetic or pharmaceutical composition for oral administration, which contains as active ingredient, at least one flavanone compound or its derivatives, or a mixture thereof, in an efficient amount to prevent, alleviate or treat skin, hair and/or coat disorders.
2. A composition according to claim 1, wherein the flavanone compounds is isosacuranetin, naringin, hesperidin, eriodictyol, poncirin, neoeriodictin.
3. A composition according to claim 1, wherein the derivatives are the aglycone, chalcone, glycosylated or methylated forms of the flavanone or sulfated and glucuronidated forms which are product of their metabolism in blood.
4. A composition according to claim 1, wherein the derivative is obtained by enzymatic treatment, or synthetically produced.
5. A composition according to any of claims 1 to 4, in which the flavanone compound is extracted from pulp or peel of Citrus fruits such as orange, lemon, bitter orange or grapefruit.
6. A composition according to any of claims 1 to 5, which further contains other active compounds such as vitamin C, vitamin E, carotenoids, ubiquinones, catechins, coffee extracts containing polyphenols and/or diterpenes, extracts of chicory, ginkgo biloba extracts, grape or grape seed extracts rich in proanthocyanidins, spice extracts, soy extracts, other sources of flavonoids with antioxidant activity, fatty acids, prebiotic fibers, probiotic microorganisms, taurine, resveratrol, aminoacids, selenium or precursors of glutathione.
7. A composition according to any of claims 1 to 5, which is milk, yogurt, curd, cheese,

fermented milks, milk based fermented products, ice-creams, milk based powders, infant formulae, cereal products, fermented cereal based products, mineral water, chocolate or pet food, dietary supplement, tablets or cosmetic products.

- 5 8. Use of at least one flavanone compound or its derivatives, or a mixture thereof, as active ingredient for the preparation of a composition intended to prevent, alleviate or treat skin, hair and/or coat disorders or damages.
- 10 9. Use of at least one flavanone compound or its derivatives, or a mixture thereof, as active ingredient for the preparation of a composition intended to improve skin, hair and/or coat conditions when administered to human or pet animal.
- 15 10. The use according to claim 8 or 9, wherein the flavanone compounds is isosacuranetin, naringin, hesperidin, eriodictyol, poncirin, neoeriocitrin or derivatives selected from their aglycone, chalcone, glycosylated or methylated forms or sulfated and glucuronidated forms which are product of their metabolism in blood.
- 20 11. The use according to any of claims 8 to 10, in which the flavanone compound is extracted from pulp or peel of Citrus fruits such as orange, lemon, bitter orange or grapefruit.
- 25 12. The use according to any of claims 8 to 11, wherein the composition is a cosmetic, nutritional or pharmaceutical composition.
- 30 13. The use according to any of claims 8 to 12, wherein the flavanone compounds, its derivatives or mixtures thereof is present in an amount of from 0.01 mg to 1g, preferably 0.1 mg to 800 mg of aglycone equivalent of the flavanone compound.
14. The use according to any of claims 8 to 13, wherein skin disorders or damages are produced by ageing or a stress situation such as chemical, biological or a physical

stress, exposure to oxidants or carcinogens, to bacteria, viruses, fungi, lipids derived from surrounding cells and/or microbes, or exposure to UV-irradiation.

- 5 15. The use according to any of claims 8 to 14, in which the composition is intended to improve skin photoprotection, hydration, dryness, firmness, elasticity, oilness, thickness, regular pigmentation, barrier function, skin elasticity, to prevent oxidative status, risks of cancer, inflammation or modulate sebum production or composition, and/or reduce signs of ageing.
- 10 16. The use according to any of claims 8 to 14, in which the composition is intended to improve hair and coat gloss, hair density, color, oilness, to ameliorate hair fibre diameter, sebum production and to prevent hair and coat loss.

Fig. 1





Fig. 2

Hesperidin-growth trial AQ-04-01

- (1) control group sacrificed at 12 w old
- (2) group dose 1 (0.1%) sacrificed at 12 w old
- (3) group dose 2 (0.5%) sacrificed at 12 w old

Fig. 3




Fig. 4

